[Proangiogenic cell-based therapy for treatment of ischemic diseases].
The application of endothelial progenitor cells (EPC) cell-based therapy for regenerative medicine constitutes a promising therapeutic avenue for the treatment of cardiovascular diseases. Based on experimental studies demonstrating that bone marrow-, blood- or tissue-derived stem/progenitor cells improve the functional recovery after ischemia, clinical trials were initiated to address this new therapeutic concept. Although autolougous cell therapy was shown to improve perfusion and function of ischemic tissues, a number of issues remain to be adressed. The nature of the mobilizing, migratory and homing signals, and the mechanisms of action need to be identified and further defined. In addition, strategies to enhance homing, survival and therapeutic potential of EPC need to be developped to improve therapeutic effect and counteract EPC dysfunction in aged patients with cardiovascular risk factors. The present review article will discuss the mechanisms of action of different types of adult stem cells and several approaches to improve their therapeutic efficiency.
Silvestre
Jean-Sébastien
JS
Paris-Cardiovascular Research Center-Inserm U970, Hôpital européen Georges Pompidou, 56, rue Leblanc, 75015 Paris, France. jean-sebastien.silvestre@inserm.fr
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D042783:Endothelial Cells / Q000637:transplantation*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D006801:Humans; D007511:Ischemia / Q000601:surgery*; D018919:Neovascularization, Physiologic; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*